Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month

The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.

from Health and Science https://ift.tt/bX9Jgx7
https://ift.tt/jNQzExi
https://ift.tt/sYyU8ej